Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NELARABINE Cause Malignant neoplasm progression? 28 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Malignant neoplasm progression have been filed in association with NELARABINE (Nelarabine). This represents 3.8% of all adverse event reports for NELARABINE.

28
Reports of Malignant neoplasm progression with NELARABINE
3.8%
of all NELARABINE reports
17
Deaths
6
Hospitalizations

How Dangerous Is Malignant neoplasm progression From NELARABINE?

Of the 28 reports, 17 (60.7%) resulted in death, 6 (21.4%) required hospitalization, and 3 (10.7%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NELARABINE. However, 28 reports have been filed with the FAERS database.

What Other Side Effects Does NELARABINE Cause?

Febrile neutropenia (67) Drug ineffective (50) Myelopathy (47) Neurotoxicity (47) Neuropathy peripheral (45) Muscular weakness (42) Sepsis (39) Peripheral sensory neuropathy (38) Neutropenia (37) Off label use (37)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which NELARABINE Alternatives Have Lower Malignant neoplasm progression Risk?

NELARABINE vs NELFINAVIR NELARABINE vs NELVUTAMIG NELARABINE vs NEMOLIZUMAB NELARABINE vs NEMOLIZUMAB-ILTO NELARABINE vs NEOMYCIN

Related Pages

NELARABINE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression NELARABINE Demographics